Literature DB >> 17083612

Investigation of the interaction between buprenorphine and sufentanil during anaesthesia for ovariectomy in dogs.

Lilia A Goyenechea Jaramillo1, Joanna C Murrell, Ludo J Hellebrekers.   

Abstract

OBJECTIVE: To investigate the effect of buprenorphine pre-treatment on sufentanil requirements in female dogs undergoing ovariectomy. STUDY
DESIGN: Randomized, 'blinded', prospective clinical study. ANIMALS: Thirty healthy female dogs referred for ovariectomy.
MATERIALS AND METHODS: Dogs were randomly assigned to one of two pre-anaesthetic treatment groups. Those in the buprenorphine group (B) received buprenorphine 20 microg kg(-1) and acepromazine 0.03 mg kg(-1) IM. Control group (C) animals received an equal volume of NaCl 0.9% and acepromazine 0.03 mg kg(-1) IM. The anaesthetic technique was identical in both groups. Pre-anaesthetic medication consisted of intravenous (IV) sufentanil (1.0 microg kg(-1)) and midazolam (0.05 mg kg(-1)) and intramuscular atropine (0.03 mg kg(-1)). Anaesthesia was induced with propofol and maintained with a constant rate infusion of sufentanil (1.0 microg kg(-1) hour(-1)) and with oxygen-isoflurane. Ventilation was controlled mechanically. Ovariectomy was performed using a standard technique. Baseline heart rate (HR) and direct mean arterial blood pressure (MAP) were recorded before the first incision. Increases in HR and MAP of > or =20% over baseline and, or spontaneous ventilation were controlled using IV sufentanil (1.0 microg kg(-1)) repeated after 5 minutes if haemodynamic variables remained elevated or attempts at spontaneous ventilation persisted. Analysis of variance was used to determine group differences in mean and median HR and MAP and to compare the maximum HR and MAP attained during surgery. Poisson regression was used to compare the number of sufentanil injections required in both groups.
RESULTS: Group B required 2.46 times more sufentanil injections (p = 0.00487) than dogs in group C to maintain haemodynamic stability and prevent spontaneous ventilation during surgery. Group B dogs also had a significantly higher (p = 0.034) marginal mean of the log maximum MAP (4.756 +/- 0.036) compared with group C (4.642 +/- 0.036).
CONCLUSIONS: Pre-treatment with buprenorphine appears to negatively influence the antinociceptive efficacy of intra-operative sufentanil. CLINICAL RELEVANCE: Withholding buprenorphine therapy 6-8 hours before anaesthesia incorporating pure mu receptor agonists is probably advisable. Alternative methods of analgesia should be provided in this period.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17083612     DOI: 10.1111/j.1467-2995.2006.00285.x

Source DB:  PubMed          Journal:  Vet Anaesth Analg        ISSN: 1467-2987            Impact factor:   1.648


  4 in total

1.  Sedative and cardiopulmonary effects of buprenorphine and xylazine in horses.

Authors:  Fernando S F Cruz; Adriano B Carregaro; Melissa Machado; Rômulo R Antonow
Journal:  Can J Vet Res       Date:  2011-01       Impact factor: 1.310

2.  Assessment of postoperative analgesia after application of ultrasound-guided regional anesthesia for surgery in a swine femoral fracture model.

Authors:  Joseph M Royal; Timothy L Settle; Michael Bodo; Eric Lombardini; Michael L Kent; Justin Upp; Stephen W Rothwell
Journal:  J Am Assoc Lab Anim Sci       Date:  2013       Impact factor: 1.232

3.  Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial.

Authors:  Paulo Vinicius Steagall; Hélène Louise Marcelle Ruel; Tomoyo Yasuda; Beatriz Paglerani Monteiro; Ryota Watanabe; Marina Cayetano Evangelista; Francis Beaudry
Journal:  BMC Vet Res       Date:  2020-05-24       Impact factor: 2.741

4.  Comparison of cardiorespiratory and anesthetic effects of ketamine-midazolam-xylazine-sufentanil and tiletamine-zolazepam-xylazine in miniature pigs.

Authors:  Zhiheng Zhang; Hui Bai; Bo Zhang; Meilun Shen; Li Gao
Journal:  PLoS One       Date:  2022-07-12       Impact factor: 3.752

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.